Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer, R Hutson, T Cella, D Reeves, J Hawkins, Robert E Guo, J Nathan, P Staehler, M de Souza, P Merchan, J
Motzer, R
Hutson, T
Cella, D
Reeves, J
Hawkins, Robert E
Guo, J
Nathan, P
Staehler, M
de Souza, P
Merchan, J
Citations
Altmetric:
Abstract
Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy.
Description
Date
2013-08-22
Publisher
Collections
Keywords
Type
Article
Citation
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. 2013, 369 (8):722-31 N Engl J Med